CHMP konkluderede imidlertid, at dette sandsynligvis ikke vil medføre en forskel i graden af beskyttelse mod infektion med S. pneumoniae efter en booster- injektion, når Prevenar anvendes som del af et rutinemæssigt immuni - seringsprogram, hvor de fleste spædbørn vaccineres.
However, the CHMP concluded that this is unlikely to lead to a difference in the rate of protection against infection with S. pneumoniae following a booster injection, when Prevenar is used as part of a routine immunisation programme in which most infants are vaccinated.